WSU Researchers Developed New Endometriosis Nanotherapy

A new targeted treatment showed promise in reducing lesions and pain during laboratory testing on mice.

Updated on Oct. 14, 2026 in Women’s Health

Microscopic view of engineered nanoparticles suspended in clear liquid, highlighting the precision of modern medical research in treating endometriosis. — Washington State University researchers have engineered a targeted nanotherapy using niclosamide to treat endometriosis, showing promise in laboratory animal trials. AI Illustration. Upload story photo >

Live Poll

Should the government and private sector increase funding for research into chronic women's health conditions?

Washington State University researchers have engineered a nanotherapy to treat endometriosis, a condition that affects 190 million women globally. The novel approach uses a nanocarrier to deliver the drug niclosamide directly to disease sites, bypassing the safety issues associated with standard oral delivery.

Why it matters

Current hormonal treatments for endometriosis often cause significant drawbacks, and surgical interventions remain limited in scope. This new method could offer a more effective path forward by targeting specific immune cells rather than affecting healthy tissue.

The study reported that the engineered nanocarrier maintains stability for 2 weeks in laboratory conditions. This allows for precise drug delivery to macrophages at the site of endometriosis lesions.

The players

Washington State University

This is the primary research institution where the team developed the new nanotherapy.

Advanced Healthcare Materials

This peer-reviewed journal published the research findings regarding the new endometriosis treatment.

The details

The team integrated a nano-sized molecule with niclosamide, a drug currently approved for tapeworm infections that previously lacked adequate solubility for this use. In laboratory tests, a single injection of the treatment successfully reduced both lesion size and pain sensitivity in mice.

October 14, 2026: The research results were officially published.
In approximately five years: Human research trials are projected to begin.

Health Landscape

This development marks a significant departure from legacy hormonal treatments by focusing on nanotechnology-enabled precision medicine. It reflects a growing shift in the scientific discipline toward site-specific therapy to improve therapeutic outcomes for patients.

While this treatment remains in the laboratory phase, it offers future hope for those struggling with the typical 7 to 10-year path to diagnosis. It may eventually provide a non-surgical alternative to existing hormone-based therapies.

The takeaway

This breakthrough provides a new potential method to manage endometriosis by targeting immune cells directly. Patients should continue to consult their healthcare providers about currently available options while this new technology advances through the development pipeline.

What happens next

The research team is currently pursuing patenting and commercialization of the technology with the ultimate goal of initiating human clinical trials in approximately five years.